GlucoTrack shares surge 17.60% premarket after USPTO approves three patents for its implantable CBGM platform, strengthening IP and commercialization prospects.

GlucoTrack (NASDAQ:GCTK) surged 17.60% in premarket trading following the U.S. Patent and Trademark Office’s approval of three key patents for its continuous blood glucose monitoring (CBGM) platform. The patents cover proprietary sensor chemistry, intravascular lead design, and low-power electronics, reinforcing the company’s intellectual property protections as it advances its fully implantable, multi-year CBGM system toward commercialization. The approvals, announced January 29, 2026, underscore Glucotrack’s progress in differentiating its technology—designed for up to three years of continuous blood glucose monitoring without wearable components—from existing interstitial fluid-based systems. CEO Paul V. Goode emphasized the patents’ role in establishing competitive barriers and supporting clinical development, aligning with the stock’s sharp premarket rise.